Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An Opportunity for Hospice Referral in Acute Myeloid Leukemia: Prognostic Significance of Hospitalization Status at Time of Second Cycle of Hypomethylating Agents for Patients Ineligible for Intensive Induction Chemotherapy.
Tremblay D, Madero-Marroquin R, Lancman G, Coltoff A, Feld J, Caro J, Sherlock E, Keyzner A, Navada S, Silverman LR, Moshier E, Zubizarreta N, Mascarenhas J. Tremblay D, et al. Among authors: silverman lr. J Palliat Med. 2020 Nov;23(11):1424-1425. doi: 10.1089/jpm.2020.0355. J Palliat Med. 2020. PMID: 33174777 No abstract available.
Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer.
Ohnuma T, Lehrer D, Ren C, Cho SY, Maniar M, Silverman L, Sung M, Gretz HF 3rd, Benisovich V, Navada S, Akahoho E, Wilck E, Taft DR, Roboz J, Wilhelm F, Holland JF. Ohnuma T, et al. Am J Cancer Res. 2013 Jun 20;3(3):323-38. Print 2013. Am J Cancer Res. 2013. PMID: 23841031 Free PMC article.
Clinical development of demethylating agents in hematology.
Navada SC, Steinmann J, Lübbert M, Silverman LR. Navada SC, et al. Among authors: silverman lr. J Clin Invest. 2014 Jan;124(1):40-6. doi: 10.1172/JCI69739. Epub 2014 Jan 2. J Clin Invest. 2014. PMID: 24382388 Free PMC article. Review.
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.
Hexner EO, Mascarenhas J, Prchal J, Roboz GJ, Baer MR, Ritchie EK, Leibowitz D, Demakos EP, Miller C, Siuty J, Kleczko J, Price L, Jeschke G, Weinberg R, Basu T, Pahl HL, Orazi A, Najfeld V, Marchioli R, Goldberg JD, Silverman LR, Hoffman R. Hexner EO, et al. Among authors: silverman lr. Leuk Lymphoma. 2015;56(9):2543-51. doi: 10.3109/10428194.2014.1001986. Epub 2015 Feb 20. Leuk Lymphoma. 2015. PMID: 25563429 Free PMC article. Clinical Trial.
Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis.
Mascarenhas J, Baer MR, Kessler C, Hexner E, Tremblay D, Price L, Sandy L, Weinberg R, Pahl H, Silverman LR, Goldberg JD, Kosiorek H, Dueck AC, Hoffman R. Mascarenhas J, et al. Among authors: silverman lr. Leuk Lymphoma. 2019 May;60(5):1343-1345. doi: 10.1080/10428194.2018.1532509. Epub 2019 Jan 22. Leuk Lymphoma. 2019. PMID: 30668266 Free PMC article. Clinical Trial. No abstract available.
91 results